Related Experiment Video

Updated: May 30, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Targeted treatment of differentiated and medullary thyroid cancer

Shannon R Bales1, Inder J Chopra

  • 1Division of Endocrinology, Diabetes, and Hypertension, University of California, Los Angeles, CA 90095, USA.

Journal of Thyroid Research
|August 10, 2011
PubMed

Insights

New targeted kinase inhibitors offer treatment options for advanced thyroid cancer. While showing some response and disease stabilization, their impact on survival and side effect profiles vary, necessitating careful patient selection.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Thyroid cancer incidence is rising, with more advanced and metastatic cases.
  • Recent breakthroughs in understanding thyroid cancer pathogenesis have spurred the development of novel therapies.

Purpose of the Study:

  • To review new targeted kinase inhibitors for advanced thyroid cancer.
  • To discuss their efficacy, side effect profiles, and appropriate patient populations.

Main Methods:

  • Review of recent literature on targeted kinase inhibitors for thyroid cancer.
  • Analysis of reported response rates, disease stabilization, and survival data.
  • Comparison of efficacy and side effect profiles across different agents.

Main Results:

  • New targeted kinase inhibitors, including those affecting BRAF V600E, RET/PTC, VEGFR, and PDGFR, are emerging.
  • Reported responses range from significant partial responses to disease stabilization.
  • Efficacy and side effect profiles vary considerably among these agents.

Conclusions:

  • Targeted kinase inhibitors represent a new therapeutic avenue for advanced thyroid cancer.
  • Patient selection is crucial due to variable efficacy, side effects, and unclear survival benefits.
  • Further research is needed to clarify the long-term impact of these agents on survival.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...